Emerging Predictive Biomarkers of Immunotherapy Sensitivity in Patients with Non-Small Cell Lung Cancer.

112 Similarly, Gainor et al reported a favorable trend in both progression-free survival and duration of response among patients with PD-L1 ≥50%. 113 Cortellini et al also observed that, within a PD-L1 ≥50% cohort treated with pembrolizumab, tobacco exposure was associated with a lower risk of progression and death.

also in 993 other papers